MW

Mark Watson

Vice President Of Platform Architecture at Nurocor

Mark Watson has a diverse work experience spanning over several companies and roles.

Mark'smost recent position is Vice President of Platform Architecture at Nurocor - Digitalized Clinical Development, where they started in April 2022. Prior to this role, they served as a Senior Software Engineer at the same company from September 2017 to April 2022.

Before joining Nurocor, Mark founded their own company called Synistralia Software, LLC in October 2014, where they worked as a Founder and Lead Developer. Mark executed a contract with Stilman Advanced Strategies, focusing on web interface development and front-end UI work in Angular and Bootstrap.

Mark also has valuable experience from their time at DSCI, where they worked as a Senior Software Engineer II from November 2002 to October 2014. Additionally, they worked at Northrop Grumman as a Software Developer from February 1997 to November 2002, specializing in developing battlefield simulation software in C++.

Mark's early career includes a role as a Research Assistant at Texas A&M University in 2000 and a Student Aide position at Southwest Research Institute from 1995 to 1997. Overall, their work experience demonstrates a strong background in software engineering, development, and leadership positions.

Mark Watson earned their Bachelor of Science degree in Computer Science from St. Mary's University from 1996 to 1999. Mark then pursued their Master of Computer Science degree at Texas A&M University from 2000 to 2002. Prior to their college education, Mark attended William Howard Taft High School from 1992 to 1996. In addition to their formal education, they obtained the ASTi Training Certification from Advanced Simulation Technology Inc. in 2011.

Location

Bryan, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Nurocor

Executives responsible for Clinical Operations are faced with ever increasing pressures to reduce costs and achieve quality by design, while meeting timelines and increasing productivity of Trial Execution Teams. Nurocor has developed an automation solution that saves $8,000,000 and 8 months for each Phase 3 trial. The Nurocor solution maximizes the value of existing system through built in connectivity enabling high value staff to focus on critical tasks not the mundane. Let Nurocor show you how; it takes only 15 minutes.


Employees

51-200

Links